Explore Erdanat 4 Tablet, containing erdafitinib 4mg. Review product information, quality checks and Washington buyer enquiries with Ernest Impex LLP.
Erdanat 4 Tablet: Erdafitinib 4mg Product Information
Looking to buy ERDAFITINIB Tablet for pharmaceutical procurement in Washington, USA? Erdanat 4 Tablet is the requested NATCO Pharma product containing erdafitinib 4mg. Buyers should confirm the actual pack, batch details, remaining shelf life and available documentation before comparing offers.
Ernest Impex LLP is the business enquiry contact for importers, pharmaceutical distributors, wholesalers and healthcare procurement teams. Availability and the requirements for the proposed transaction must be confirmed before any purchase commitment.
What Is Erdanat 4 Tablet?
Erdafitinib is an oral targeted anticancer medicine. It blocks fibroblast growth factor receptors, known as FGFRs, which can contribute to cancer-cell growth in certain tumours.
NATCO lists Erdanat in its domestic oncology portfolio. The exact strength, manufacturer details and market presentation should be checked against the offered packaging.
This medicine requires specialist prescribing. It is not suitable for every patient with bladder or urinary tract cancer.
Treatment Use and Key Benefit
In the United States, erdafitinib under the brand Balversa is approved for certain adults with locally advanced or metastatic urothelial carcinoma. Patients must have susceptible FGFR3 genetic alterations identified through an FDA-approved companion diagnostic test, and their disease must have progressed after at least one previous systemic treatment.
The U.S. indication also states that erdafitinib is not recommended for patients eligible for a PD-1 or PD-L1 inhibitor who have not received that therapy.
The key therapeutic benefit is targeting a specific cancer-growth pathway in appropriately selected patients. Clinical evidence supporting Balversa showed improved survival compared with the chemotherapy treatments studied. This does not establish identical performance or U.S. approval for Erdanat.
For buyers reviewing targeted oncology medicines, the active ingredient, brand and approved market information should remain clearly distinguished.
Product Specifications
| Specification | Details |
|---|---|
| Brand name | Erdanat 4 Tablet |
| Active ingredient | Erdafitinib |
| Stated strength | 4mg per tablet; confirm on the actual label |
| Dosage form | Oral tablet |
| Medicine category | Targeted anticancer medicine / FGFR inhibitor |
| Manufacturer supplied for this listing | Natco Pharma Ltd.; verify the offered pack |
| Procurement enquiry contact | Ernest Impex LLP |
| Labelled marketer | Confirm from the actual packaging |
| Pack quantity | Confirm before approving the quotation |
| Shelf life | Check the offered batch |
| Storage | Follow the product label |
| Intended buyers | Importers, distributors, wholesalers and healthcare procurement teams |
The 4mg strength describes the amount in one tablet. It should not be presented as the prescribed daily dose, which is determined by the treating specialist.
Ernest Impex LLP is identified here as the procurement contact. Its status as the labelled marketer or an authorised NATCO distributor has not been independently established.
Important Safety Information
Erdafitinib can cause eye disorders, including retinal problems, and can increase blood phosphate levels. Treatment requires eye examinations, laboratory monitoring and review of interacting medicines.
Other reported adverse effects include mouth inflammation, diarrhoea, nail changes and fatigue. Patients who develop changes in vision need prompt medical assessment. BALVERSA® (erdafitinib) HCP
This page provides product information for procurement teams. It does not replace the prescribing information or an oncologist’s assessment.
Quality Checks Before Ordering
For an oncology product, a clear label and traceable source are essential parts of evaluating the offer.
Request readable photographs of the carton and inner packaging. Compare the brand, strength, batch number and expiry date with the quotation and supporting records.
Before approving an order, check:
- Manufacturer identity and manufacturing-site details.
- Pack quantity and total number of tablets.
- Packaging condition and applicable seals.
- Available batch documents, including a certificate of analysis where obtainable.
- Traceable invoices and source-of-supply records.
Agree on the minimum remaining shelf life in writing. A quotation for “100 units,” for example, should clarify whether it means 100 tablets or 100 packs.
Link pharmaceutical quality checks to a relevant existing quality or supplier-verification page.
Procurement Considerations for Washington, USA
NATCO’s domestic oncology pages include an India-only marketing or sales notice. Confirm the applicable territorial restrictions for Erdanat before considering a U.S. transaction.
FDA approval of Balversa does not automatically establish approval of the Erdanat brand. Imported medicines must meet applicable U.S. requirements covering approval, registration, listing, labelling and manufacturing compliance.
This listing does not confirm routine availability or import eligibility for Erdanat in Washington.
Clear Documentation Builds Confidence
A useful supplier response should identify the exact product, pack size, available batch, remaining shelf life and commercial terms.
Ask which documents can be supplied for the specific transaction. General company certificates should not be treated as proof of approval or batch quality for every product.
For transport, follow the actual label’s storage conditions and agree on suitable packaging and receiving arrangements. Use medicine storage and transport as an internal-link point where a matching page exists.
Enquire Through Ernest Impex LLP
Send your organisation details, required quantity, preferred pack size, minimum shelf life and documentation needs. Include the complete destination address and specify Washington State or Washington, D.C.
Contact Ernest Impex LLP to request product information and assessment of the enquiry. Confirm territorial permissions and U.S. eligibility before agreeing to purchase or shipment.
Frequently Asked Questions
1. What does Erdanat 4 Tablet contain?
The requested product contains erdafitinib 4mg per tablet. Confirm the composition and strength on the actual offered pack.
2. Is erdafitinib used for every type of bladder cancer?
No. Its U.S. indication applies to defined patients with advanced urothelial carcinoma and susceptible FGFR3 alterations, alongside prior-treatment requirements.
3. Why is genetic testing important?
Testing helps identify the tumour alterations required for treatment selection. An oncology specialist must assess the result together with the patient’s clinical history.
4. What should wholesalers check before purchasing?
Verify the exact brand, strength, pack quantity, manufacturer, batch, expiry, packaging condition and source records. Request available product and batch documents.
5. Does this page confirm FDA approval for Erdanat?
No. The cited U.S. approval concerns Balversa. Approval and import eligibility for the exact Erdanat product require separate verification.
